Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.43), $0.08 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $33.6 million versus the consensus estimate of $35.25 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2023 revenue of $160-175 million, versus the consensus of $163 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.